Shots:
- The CHMP has recommended conditional approval of Zemcelpro in 30 EEA states for adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no suitable donor; EC’s decision is expected within 2mos.
- Zemcelpro (UM171 Cell Therapy) was evaluated in P-II trials for pts with high & very high-risk acute leukemias & myelodysplasias with limited therapy options & poor outcomes with SoCs, incl. those with TP53 mutations, refractory/active disease, or who require another transplant
- Zemcelpro will be advanced in a P-III trial for mentioned pts, plus additional filings are planned in multiple regulatory bodies incl. the US, Canada, the UK, & Switzerland
Ref: Prnewswire | Image: Excellthera| Press Release
Related News:- Incyte’s Monjuvi Regimen Receives the US FDA Approval for R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
